Fiera Capital Corp Trims Holdings in Biohaven Ltd. $BHVN

Fiera Capital Corp trimmed its stake in shares of Biohaven Ltd. (NYSE:BHVN) by 1.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 575,110 shares of the company’s stock after selling 6,565 shares during the quarter. Fiera Capital Corp owned 0.56% of Biohaven worth $8,115,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in BHVN. Candriam S.C.A. increased its position in shares of Biohaven by 36.7% during the second quarter. Candriam S.C.A. now owns 129,243 shares of the company’s stock valued at $1,824,000 after buying an additional 34,664 shares during the period. Police & Firemen s Retirement System of New Jersey increased its holdings in Biohaven by 10.7% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 21,016 shares of the company’s stock worth $297,000 after acquiring an additional 2,030 shares during the period. Geode Capital Management LLC lifted its stake in Biohaven by 3.7% in the 2nd quarter. Geode Capital Management LLC now owns 2,030,919 shares of the company’s stock worth $28,660,000 after purchasing an additional 71,939 shares in the last quarter. Quinn Opportunity Partners LLC bought a new position in Biohaven in the 2nd quarter valued at $423,000. Finally, Simplify Asset Management Inc. purchased a new position in shares of Biohaven during the 2nd quarter valued at $1,360,000. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Analysts Set New Price Targets

BHVN has been the subject of several research analyst reports. Royal Bank Of Canada dropped their price objective on Biohaven from $19.00 to $9.00 and set a “sector perform” rating for the company in a research note on Thursday, November 6th. William Blair reiterated a “market perform” rating on shares of Biohaven in a research report on Tuesday. Morgan Stanley reissued an “overweight” rating on shares of Biohaven in a report on Wednesday, November 5th. TD Cowen lowered their target price on shares of Biohaven from $50.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Finally, Sanford C. Bernstein reiterated a “market perform” rating and set a $9.00 target price (down from $34.00) on shares of Biohaven in a research report on Thursday, November 6th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $33.21.

Biohaven Stock Performance

NYSE:BHVN opened at $8.08 on Friday. Biohaven Ltd. has a 1-year low of $7.48 and a 1-year high of $50.40. The company has a debt-to-equity ratio of 1.91, a current ratio of 2.86 and a quick ratio of 3.82. The business has a 50 day moving average of $14.51 and a 200 day moving average of $15.32. The company has a market capitalization of $855.35 million, a price-to-earnings ratio of -1.06 and a beta of 1.10.

Biohaven (NYSE:BHVN) last posted its quarterly earnings results on Monday, November 10th. The company reported ($1.64) EPS for the quarter, topping the consensus estimate of ($1.91) by $0.27. On average, sell-side analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.